CT001 ready for shipment to initial U.S. hospitals as launch activities commence

Initial U.S. commercial supply of CT001 now available for shipment Launch activities initiated with… Initial U.S. commercial supply of CT001 now available for shipment Launch activities initiated with selected U.S. hospitals Copenhagen, Denmark – 27 August 2026 – Cessatech A/S (“Cessatech” or the “Company”), a late-stage paediatric specialty company developing and commercializing hospital medicines for children, today announced the successful release of CT001 by its U.S. manufacturing partner, STAQ Pharma. This makes CT001 (sufentanil/ketamine nasal spray) available for shipment to initial U.S. hospitals and enables launch activities to begin. The release of the first commercial batch marks an important operational milestone, establishing initial product availability in the United States and enabling Cessatech and its collaboration partners to begin launch activities with selected hospitals. Comment from Jes Trygved, CEO “We would like to recognise the team at STAQ Pharma for the significant effort, dedication and expertise that made this important milestone possible. Completing and releasing the first commercial batch of CT001 is a major achievement and reflects the hard work invested throughout the manufacturing process. We now look forward to working closely with our partners as we begin the next phase and build a successful launch in the United States. We recognise that establishing CT001 in the market will take time, but this milestone provides an important foundation for the work ahead.” Release Link Related articles Releases 27. September, 2026 EUSEM Press release: Nasal spray brings pain relief for children treated in the emergency department Paris, France: A treatment for pain, that is delivered via a nasal spray, offers... Read more Releases 24. July, 2026 Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu See also the updated Q&A documentation related to the Release: Link The European Medicines... Read more Releases 12. June, 2026 Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children ... Read more Stay up to date! Subscribe and get notified on Cessatech's latest news. An acceptance email will be sent to you, please check your spam. Please leave this field empty Almost there! Please check your inbox to confirm your subscription to Cessatech.

The release as fetched from its publisher. cessatech.com ↗